HUP0203213A3 - Use of 2-imidazolyl substituted carbinols for production of medicaments for treatment or prophylaxis of ischaemic conditions - Google Patents

Use of 2-imidazolyl substituted carbinols for production of medicaments for treatment or prophylaxis of ischaemic conditions

Info

Publication number
HUP0203213A3
HUP0203213A3 HU0203213A HUP0203213A HUP0203213A3 HU P0203213 A3 HUP0203213 A3 HU P0203213A3 HU 0203213 A HU0203213 A HU 0203213A HU P0203213 A HUP0203213 A HU P0203213A HU P0203213 A3 HUP0203213 A3 HU P0203213A3
Authority
HU
Hungary
Prior art keywords
prophylaxis
medicaments
treatment
production
imidazolyl substituted
Prior art date
Application number
HU0203213A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of HUP0203213A2 publication Critical patent/HUP0203213A2/hu
Publication of HUP0203213A3 publication Critical patent/HUP0203213A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0203213A 1999-10-27 2000-10-14 Use of 2-imidazolyl substituted carbinols for production of medicaments for treatment or prophylaxis of ischaemic conditions HUP0203213A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19951701A DE19951701A1 (de) 1999-10-27 1999-10-27 Verwendung von 2-Imidazolyl-substituierten Carbinolen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
PCT/EP2000/010126 WO2001030327A2 (de) 1999-10-27 2000-10-14 Verwendung von 2-imidazolyl-substituierten carbinolen zur herstellung eines medikaments zur behandlung oder prophylaxe von durch ischämischen zuständen

Publications (2)

Publication Number Publication Date
HUP0203213A2 HUP0203213A2 (en) 2003-05-28
HUP0203213A3 true HUP0203213A3 (en) 2003-07-28

Family

ID=7927020

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203213A HUP0203213A3 (en) 1999-10-27 2000-10-14 Use of 2-imidazolyl substituted carbinols for production of medicaments for treatment or prophylaxis of ischaemic conditions

Country Status (30)

Country Link
US (1) US6291502B1 (enExample)
EP (1) EP1227811B1 (enExample)
JP (1) JP2003512419A (enExample)
KR (1) KR20020060213A (enExample)
CN (1) CN1188125C (enExample)
AR (1) AR026241A1 (enExample)
AT (1) ATE257702T1 (enExample)
AU (1) AU778836B2 (enExample)
BR (1) BR0015024A (enExample)
CA (1) CA2388956A1 (enExample)
CZ (1) CZ295925B6 (enExample)
DE (2) DE19951701A1 (enExample)
DK (1) DK1227811T3 (enExample)
EE (1) EE200200218A (enExample)
ES (1) ES2213621T3 (enExample)
HK (1) HK1048938B (enExample)
HR (1) HRP20020362A2 (enExample)
HU (1) HUP0203213A3 (enExample)
IL (1) IL149208A0 (enExample)
NO (1) NO20021909D0 (enExample)
NZ (1) NZ518586A (enExample)
PL (1) PL355911A1 (enExample)
PT (1) PT1227811E (enExample)
RU (1) RU2257205C2 (enExample)
SK (1) SK5512002A3 (enExample)
TR (1) TR200201140T2 (enExample)
TW (1) TWI246424B (enExample)
WO (1) WO2001030327A2 (enExample)
YU (1) YU20902A (enExample)
ZA (1) ZA200203035B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726829B2 (en) * 1997-04-08 2004-04-27 Scimed Life Systems, Inc. Method of manufacturing a stent
AU2003201273A1 (en) * 2002-01-04 2003-07-30 Poseidon Pharmaceuticals A/S Potassium channel modulators
AR049847A1 (es) * 2004-07-29 2006-09-06 Merck & Co Inc Inhibidores de los canales de potasio
RU2373934C1 (ru) * 2008-03-19 2009-11-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
US10040767B2 (en) 2014-05-15 2018-08-07 Peloton Therapeutics, Inc. Benzimidazole derivatives and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE793407A (fr) * 1971-12-28 1973-06-28 Hoechst Ag Imidazolyl - (2) -carbinols ayant une activite hypolipidemique et leur procede de preparation
BE794940A (fr) * 1972-02-04 1973-08-02 Gist Brocades Nv Nouveaux composes anorexigenes
US4152441A (en) 1972-02-04 1979-05-01 Gist-Brocades N.V. Analgesic imidazolemethanols
US5063220A (en) * 1988-10-21 1991-11-05 Syntex Pharmaceuticals, Ltd. Parenteral formulations of 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl)piperazine
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
DE69717627T2 (de) 1996-06-27 2003-09-18 Janssen Pharmaceutica N.V., Beerse N-4-(heteroarylmethyl)phenyl-heteroarylaminderivate

Also Published As

Publication number Publication date
HUP0203213A2 (en) 2003-05-28
HK1048938A1 (en) 2003-04-25
CZ20021452A3 (cs) 2002-07-17
HK1048938B (zh) 2005-06-10
NO20021909L (no) 2002-04-23
TR200201140T2 (tr) 2002-11-21
DE50005040D1 (de) 2004-02-19
KR20020060213A (ko) 2002-07-16
DE19951701A1 (de) 2001-05-03
SK5512002A3 (en) 2002-08-06
ZA200203035B (en) 2003-03-14
ES2213621T3 (es) 2004-09-01
WO2001030327A2 (de) 2001-05-03
CA2388956A1 (en) 2001-05-03
CN1188125C (zh) 2005-02-09
RU2257205C2 (ru) 2005-07-27
PL355911A1 (en) 2004-05-31
NZ518586A (en) 2004-07-30
US6291502B1 (en) 2001-09-18
JP2003512419A (ja) 2003-04-02
PT1227811E (pt) 2004-05-31
RU2002113666A (ru) 2004-01-10
YU20902A (sh) 2004-11-25
BR0015024A (pt) 2002-06-18
DK1227811T3 (da) 2004-04-19
NO20021909D0 (no) 2002-04-23
EP1227811B1 (de) 2004-01-14
CN1373663A (zh) 2002-10-09
AR026241A1 (es) 2003-02-05
TWI246424B (en) 2006-01-01
AU1138201A (en) 2001-05-08
EP1227811A2 (de) 2002-08-07
AU778836B2 (en) 2004-12-23
HRP20020362A2 (en) 2004-02-29
EE200200218A (et) 2003-06-16
WO2001030327A3 (de) 2002-03-14
ATE257702T1 (de) 2004-01-15
CZ295925B6 (cs) 2005-11-16
IL149208A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
PL369006A1 (en) Preparation for the prophylaxis of restenosis
AU2003205737A1 (en) Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU2002227958A1 (en) Use of moulding compounds for producing treatment devices
HUP0104963A3 (en) Compositions for the treatment of skin diseases
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU2002303145A1 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
HUP0203213A3 (en) Use of 2-imidazolyl substituted carbinols for production of medicaments for treatment or prophylaxis of ischaemic conditions
IL163871A0 (en) Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
AU2003237598A8 (en) Process for the preparation of highly pure rabeprazole sodium salt
AU2001239301A1 (en) Use of ectoin or ectoin derivatives for the prophylaxis and/or treatment of uv-induced immunosuppression
SI1227811T1 (en) Use of 2-imidazolyl substituted carbinols for production of a medicament for treatment or prophylaxis of disease states as a result of ischaemic conditions
AU2002365621A8 (en) Composition for treating the surface of the skin
AU2900100A (en) Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss
PT1698338E (pt) S-metil-di-hidro-ziprasidona para o tratamento de distúrbios psiquiátricos
HUP0203774A3 (en) Use of 2-amino-3,4-dihydro-quinazolines for producing medicaments for treating or preventing diseases caused by ischaemic conditions
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2002336984A1 (en) Use of C2-substituted Indane-1-ol systems for producing medicaments for the prophylaxis or treatment of obesity
AU2002351975A8 (en) Production of alpha-keto butyrate
PL371270A1 (en) Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine
GB2401044B (en) A composition for use in the treatment or prophylaxis of a skin condition in a subject
AU2002336985A1 (en) Use of C2-substituted Indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity
EP1488800A4 (en) MEDICINE FOR THE TREATMENT OF PROTOCOL DISEASES

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished